Nasdaq adds Moderna stock to Nasdaq-100 before October 9, 2026

Published on 10/12/2026 at 11:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock trades at EUR 200.30 on October 12, 2026. Second-quarter revenue rose 2.00 percent to USD 145.00 million on July 31, 2026.

Key points in brief

Nasdaq added Moderna to the Nasdaq-100 before the October 9, 2026 session.
Moderna stock was trading at EUR 200.30 at Lang & Schwarz on October 12, 2026.
Second-quarter 2026 revenue rose 2.00 percent year over year to USD 145.00 million.
The company is scheduled to present Phase 3 melanoma data and host an investor webcast on October 24, 2026.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) was trading at EUR 200.30 at Lang & Schwarz on October 12, 2026, at 11:44 a.m. CEST. Nasdaq announced on October 1, 2026, that Moderna would join the Nasdaq-100 before the October 9 session.

Nasdaq-100 inclusion changes the backdrop

The index addition gives Moderna a new position among the 100 largest non-financial companies listed on Nasdaq. The Nasdaq release said the benchmark was tracked by more than 200 investment products with over USD 800 billion in assets under management.

Moderna's market capitalization stood at USD 89.3 billion on October 9, 2026, while the Nasdaq-listed MRNA share was last quoted at USD 225.00 at 4:00 p.m. EDT that day. The euro quote from Lang & Schwarz is a separate German-market reference.

Revenue improved in second quarter

In the second quarter of 2026, Moderna reported revenue of USD 145.00 million and a net loss of USD 782.00 million. Yahoo Finance reported that revenue increased 2.00 percent year over year, while the loss narrowed from USD 825.00 million in the second quarter of 2025.

The earnings call also set the operating frame for the rest of 2026. Management reiterated revenue growth of up to 10.00 percent for the year and projected cash and investments of USD 4.7 billion to USD 5.2 billion at year-end, subject to execution and vaccine demand.

What does the oncology schedule add?

Moderna announced on September 21, 2026, that Phase 3 data for intismeran autogene in resected stage IIB to IV melanoma had been selected for an ESMO Presidential Symposium. The company said it would host an investor webcast on October 24, 2026, at 7:00 p.m. CEST.

The clinical backdrop includes historical Phase 2 results presented on June 1, 2026, when intismeran autogene combined with pembrolizumab reduced the risk of recurrence or death by 49.00 percent and the risk of distant metastasis or death by 59.00 percent versus pembrolizumab alone, according to Moderna.

Two October dates matter

Moderna lists the ESMO Presidential Symposium for October 24, 2026, at 4:30 p.m. CEST and the investor webcast for the same date at 7:00 p.m. CEST. A further Phase 3 non-small-cell lung cancer poster is scheduled for October 26, 2026.

For investors, the key tension is visible in the numbers: the company is still loss-making, while the oncology pipeline and index inclusion have lifted the market value to USD 89.3 billion. The October clinical presentations therefore place execution and data quality alongside the stock's expanded index visibility.

Moderna stock stays in trading

At Lang & Schwarz, Moderna stock was trading at EUR 200.30 on October 12, 2026, at 11:44 a.m. CEST. Its primary listing is on NASDAQ, where the last quoted price was USD 225.00 on October 9, 2026, at 4:00 p.m. EDT.

Market context: Market report Nasdaq Composite.